The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 26, 2021
Filed:
Sep. 08, 2020
Applicant:
Syneurx International (Taiwan) Corp., New Taipei, TW;
Inventors:
Guochuan Emil Tsai, Pasadena, CA (US);
Yi-Wen Mao, New Taipei, TW;
Lu-Ping Lu, New Taipei, TW;
Wei-Hua Chang, New Taipei, TW;
Han-Yi Hsieh, New Taipei, TW;
Jhe Wei Hu, New Taipei, TW;
Tsai-Miao Shih, New Taipei, TW;
ChanHui Huang, New Taipei, TW;
Assignee:
SYNEURX INTERNATIONAL (TAIWAN) CORP., New Taipei, TW;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/351 (2006.01); A61P 31/14 (2006.01); A61K 31/7024 (2006.01); A61K 36/82 (2006.01); A61K 36/22 (2006.01); A61K 36/49 (2006.01); A23L 33/105 (2016.01); A61K 31/235 (2006.01); A61K 9/00 (2006.01); A61K 31/513 (2006.01); A61K 31/427 (2006.01); A61K 31/4709 (2006.01); A61K 31/472 (2006.01); A61K 31/4433 (2006.01); A61K 31/685 (2006.01); A61K 38/21 (2006.01); A61K 31/46 (2006.01); A61K 38/16 (2006.01); A61K 39/395 (2006.01); A61K 31/675 (2006.01); A61K 31/395 (2006.01); A61K 31/353 (2006.01); A61K 31/499 (2006.01); A61K 31/16 (2006.01); A61K 31/426 (2006.01); A61K 31/4045 (2006.01); A61K 31/343 (2006.01); A61K 31/13 (2006.01); A61K 31/4245 (2006.01); A61K 31/7072 (2006.01); A61K 31/708 (2006.01); A61K 31/506 (2006.01); A61K 31/52 (2006.01); A61K 31/551 (2006.01); A61K 31/4985 (2006.01); A61K 31/553 (2006.01); A23L 33/00 (2016.01); A23L 33/10 (2016.01);
U.S. Cl.
CPC ...
A61K 31/351 (2013.01); A23L 33/10 (2016.08); A23L 33/40 (2016.08); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 31/13 (2013.01); A61K 31/16 (2013.01); A61K 31/235 (2013.01); A61K 31/343 (2013.01); A61K 31/353 (2013.01); A61K 31/395 (2013.01); A61K 31/4045 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/4245 (2013.01); A61K 31/4433 (2013.01); A61K 31/46 (2013.01); A61K 31/472 (2013.01); A61K 31/4709 (2013.01); A61K 31/499 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 31/675 (2013.01); A61K 31/685 (2013.01); A61K 31/708 (2013.01); A61K 31/7072 (2013.01); A61K 38/16 (2013.01); A61K 38/21 (2013.01); A61K 38/212 (2013.01); A61K 38/217 (2013.01); A61K 39/3955 (2013.01); A61P 31/14 (2018.01); A23V 2002/00 (2013.01);
Abstract
A method of treating coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises one or more compounds of Formula (I): or a pharmaceutically acceptable salt thereof.